References

1. Lezoual’h F, Skutella T, Widmann M, et al. Melatonin prevents oxidative stress-induced cell death in hippocampal cells. NeuroReport 1996;7:2071-7.

2. Borlongan CV, Yamamoto M, Takei N, et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 1998;12:725-31.

3. Chen ST, Chuang JI. The antioxidant melatonin reduces cortical neuronal death after intrastriatal injection of kainate in the rat. Exp Brain Res 1999;124:241-7.

4. Mayo JC, sainz RM, Uria H, et al. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson’s disease. J Pineal Res 1998;24:179-92.

5. Hasegawa A, Ohtsubo K, Mori W. Pineal gland in old age; quantitative and qualitative morphological study of168 human autopsy cases. Brain Res 1987;409:343-9.

6. Swaab DF. In: AminoffMJ, Francois B, Swaab DF, editors. The human hypothalamus basic and clinical aspects. Handbook of Clinical Neurology, vol 79. Amsterdam: Elsevier; 2003. p. 63-123.

7. Arendt J. Melatonin and the Mammalian Pineal Gland. London: Chapman & Hall; 1995. p. 27-59.

8. Dai J, Swaab DF, van der Vliet J, et al. Postmortem tracing reveals the organization of hypothalamic projections of the suprachiasmatic nucleus in the human brain. J Comp Neurol 1998;400:87-102.

9. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993;49:654-64.

10. Coon SL, Del Olmo E, Young III WS, et al. Melatonin synthesis enzymes in Mecaca mulatta: focus on arylalkylamine N-acetyltransfer- ase (EC 2. 3. 1. 87). J Clin Endocrinol Metab 2002;87:4699-706.

11. Wu YH, Feenstra MG, Zhou JN, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003;88: 5898-906.

12. Dai J, Van Der Vliet J, Swaab DF, et al. Humans retinohypothalamic tract as revealed by in vitro post-mortem tracing. J Comp Neurol 1998; 397:357-70.

13. Teclemariam-Mesbah R, Ter Horst GJ, Postema F, et al. Anatomical demonstration of the suprachiasmatic nucleus-pineal pathway. J Comp Neurol 1999;406:171-82.

14. Skene DJ, Lockely SW, James K, et al. Correlation between urinary cortisol and 6-sulphatoxymeltonin rhythms in field studies of blind subjects. Clin Endocrinol 1999;50:715-9.

15. Karasek M, Stankiewicz A, Bandurska-Stankiewicz E, et al. Melatonin concentrations in patients with large goiter before and after surgery. Neuroendocrinol Lett 2000;21:437-9.

16. Bruce J, Tamarkin L, Riedel C, et al. Sequential cerebrospinal fluid and plasm sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J Clin Endocrinol Metab 1991;72:819-23.

17. Oxenkrug GF, Anderson GF, Gragovic L, et al. Circadian rhythms of human pineal melatonin, related indoles, and beta adrenoreceptors: post-mortem evaluation. J Pineal Res 1990;9:1-11.

18. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999;55:111-5.

19. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two dinstinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997;19:91-102.

20. Fisher S, Smolnik R, Herms M, et al. Melatonin acutely improves the neuroendocrine architecture of sleep in blind individuals. J Clin Endocrinol Metab 2003;88:5315-20.

21. Spitzer RL, Terman M, Williamns JBW, et al. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomised, double-blind trial. Am J Psychiatry 1999; 156:1392-6.

22. Herxhaimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag (Cochrane Review). Cochrane Library, Issue 3. Oxford: Update Software; 2001. p. 8.

23. Westchester IL. The international classification of sleep disorders: diagnostic and coding manual. Am Acad Sleep Med 2005.

24. Weitzman ED, Czeister CA, Coleman RM, Spielman AJ, Zimmerman JC, Dement W. Delayed sleep phase syndrome: a chronobiological disorder with sleep-onset insomnia. Arch Gen Psychiatry 1981;38: 137-46.

25. Kerkhof G, Vian Vianen B. Circadian phase estimation of chronic insomniacs relates to their sleep characteristics. Arch Physiol Biochem 1999;107:383-92.

26. Watanabe T, Kajimura N, Kato M, et al. Sleep and circadian rhythm disturbances in patients with Delayed Sleep Phase Syndrome. Sleep 2003;26:657-61.

27. Strogatz Sh, Kronauer RE. Circadian wake maintenance zones and insomnia in man. Sleep Res 1985;14:219.

28. Dawson D, Lack L, Morris M. Phase resetting of the human circadian pacemaker with use of a single pulse of bright light. Chronobiol Int 1999;10:94-102.

29. Sack R, Lewy A, Hughes R. Use of melatonin for sleep and circadian rhythm disorders. Ann Med 1998;30:115-21.

30. Lewy A, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to phase-response curve. Chronobiol Int 1992;9:380-92.

31. Revell VL, Burgess HJ, Gazda CJ, Smith MR, Fogg LF, Eastman CI. Advancing human circadian rhythms with afternoon melatonin and morning intermittent bright light. J Clin Endocrinol Metab 2006;91: 54-9.

32. Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: A meta-analysis. J Gen Intern Med 2005;20:1151-8.

33. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41-50.

34. Hardeland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res 2003;34:233-4.

35. Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggler B, Harderland R. Melatonin in Alzheimer’s disease and other neurodegenerative disorders. Behav Brain Funct 2006:2-15.

36. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical pro­perties and potential mechanism: melatonin as a broad spectrum anti­oxidant and free rdical scavenger. Curr Top Med Chem 2002;2:181-97.

37. Buyukavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savasan

S. Melatonin cytotoxicity in human leukaemia cells: relation with its prooxidant effect. Fundam Clin Pharmacol 2006;20:73-9.

38. Lahiri DK, Ge YW, Sharman EH, Bondy SC. Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6- hydroxymelatonin sulphate in the cerebral cortex than serum, heart, liver and kidney tissues. J Pineal Res 2004;36:217-23.

39. Sanchez-Moreno C, Dorfman SE, Lichtenstein AH, Martin A. Dietary fat type affects vitamins C and E and biomarkers of oxidative status in peripheral and brain tissue of golden Syrian hamsters. JNutr 2004;134: 655-60.

40. Filadelfi AM, Castrucci AM. Comparative aspects of the pineal melatonin system of poikilothermic vertebrates. J Pineal Res 1996;20: 175-86.

41. Kotler M, Rodriguez C, Sainz RM, Antolin I, Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998;24:83-9.

42. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004;36:1-9.

43. Anisimov SV, Popovic N. Genetic aspects of melatonin biology. Rev Neurosci 2004;15:209-30.

44. Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S. Free radical- mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci 2001;939: 200-15.

45. Conway S, Drew JE, Mowat P, Barret P, Delagrange P, Morgan PJ. Chimeric melatonin mtl and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mtl receptor. J Biol Chem 2000;275: 20602-9.

46. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 2000;29:129-37.

47. Carlberg C, Wiesenberg I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase. An unexpected relationship. J Pineal Res 1995;18:171-8.

48. Yu BP, Chung HV. Adaptive mechanism to oxidative stress during aging. Mech Ageing Dev 2006;127:436-43.

49. Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol 2003;38:199-206.

50. Duffy JF, Zeitzer JM, Rimmer DW, et al. Peak of circadian melatonin rhythm occurs later within the sleep of older subjects. Am J Physiol Endocrinol Metab 2002;282:E297-303.

51. Kunz D, Schmitz S, Mahlberg R, et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsycho­pharmacology 1999;21:765-72.

52. Kunz D, Bes F, Schlattmann P, et al. On pineal calcification and its relation to subjective sleep perception: a hypothesis-driven pilot study. Psychiatry Res 1998;82:187-91.

53. Urata Y, Honma S, Goto S, et al. Melatonin induces glutamylcysteine synthase mediated by activator protein-I in human vascular endothelial cells. Free Radic Biol Med 1999;27:838-47.

54. Martin M, Macias G, Escames G, et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res

2000;28:242-8.

55. Harrison T, Churcher I, Beher D. Gamma-secretase as a target for drug intervention in Alzheimer’s disease. Curr Opin Drug Discov Devel 2004;7:709-19.

56. Zatta P, Tognon G, Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J Pineal Res 2003;35: 98-103.

57. Acuna-Castroviejo D, Martin M, Macias M, et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001;30: 65-74.

58. Liu RY, Zhou JN, Van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999;84:323-7.

59. Beal MF. Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol 1996;6:661-6.

60. Floyd RA, Hensley K. Oxidative stress in brain aging, Implications fot therapeutics of neurodegenerative diseases. Neurobiol Aging 2002;23: 795-807.

61. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann N Y Acad Sci 2004;1012:153-63.

62. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer’s disease:the two-hit hypothesis. Lancet Neurol 2004;3:219-26.

63. Cheng Y, Feng Z, Zhang QZ, Zhang JT. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin 2006;2:129-39.

64. Blennow K, Cowburn RF. The neurochemistry of Alzheimer’s disease. Acta Neurol Scand 1996;168(Suppl):77-86.

65. Ancoli -Israel S, Klauber MR, Jones DW, et al. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 1997;20:18-23.

66. Martin J, Marler M, Shochat T, et al. Circadian rhythms of agitation in institutionalized patients with Alzheimer’s disease. Chronobiol Int 2000;17:405-18.

67. Ohashi Y, Okamoto N, Uchida K, et al. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry 1999;45:1646-52.

68. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005;38:145-52.

69. Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003;35: 125-30.

70. Pappola MA, Chyan YJ, Poeggeler B, et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: Implica­tions for Alzheimer’s disease. J Neural Transm 2000;107:203-31.

71. Rousseau A, Petren S, Plannthin J, et al. Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm 1999;106:883-8.

72. Reiter RJ, Tan DX, Machester LC, et al. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. Ann N Y Acad Sci 2002;959:238-50.

73. Pardo CA, Martin LJ, Troncoso JC, et al. The human pineal gland in aging and Alzheimer’s disease: patterns of cytoskeletal antigen immunoreactivity. Acta Neuropathol 1990;80:535-40.

74. Liu RY, Zhou JN, Hoogenduk WJ, et al. Decreased vasopressing gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 2000;59: 314-22.

75. Van De Nes JA, Kamphorst W, Ravid R, et al. Comparison of beta­protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer’s disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol 1998;96:129-38.

76. Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation ofthe human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 1999;58:29-39.

77. Campbell SS, Kripke DF, Gillin JC, et al. Exposure to light in healthy elderly subjects and Alzheimer’s patients. Physiol Behav 1998;42: 141-4.

78. Blanks JC, Torigoe Y, Hinton DR, et al. Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 1996;17:377-84.

79. Blanks JC, Schmidt SY, Torigoe T, et al. Retinal pathology in Alzheimer’s disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging 1996;17:385-95.

80. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study. Arch Gerontol Geriatr 2000;31:65-76.

81. Brusco LI, Marquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuroendocrinol. Letter 2000;21:39-42.

82. Cardinali DP, Brusco LI, Liberczuk C, et al. REVIEW. The use of melatonin in Alzheimer’s disease. Neuroendocrinol Lett 2002;23:20-3.

83. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo­controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003;26:893-901.

84. Sefarty M, Kennel-Webb S, Warner J, et al. Double blind rendomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry 2002;17:1120-7.